JP2011511810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511810A5 JP2011511810A5 JP2010546107A JP2010546107A JP2011511810A5 JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5 JP 2010546107 A JP2010546107 A JP 2010546107A JP 2010546107 A JP2010546107 A JP 2010546107A JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- amino
- substituents
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 706
- 150000001875 compounds Chemical class 0.000 claims description 463
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 275
- 125000001424 substituent group Chemical group 0.000 claims description 237
- -1 cyano, hydroxy Chemical group 0.000 claims description 224
- 239000000203 mixture Substances 0.000 claims description 183
- 125000003545 alkoxy group Chemical group 0.000 claims description 142
- 229910052736 halogen Inorganic materials 0.000 claims description 141
- 150000002367 halogens Chemical class 0.000 claims description 141
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 137
- 125000003282 alkyl amino group Chemical group 0.000 claims description 136
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 125
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 125
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 112
- 125000000304 alkynyl group Chemical group 0.000 claims description 99
- 229910052799 carbon Inorganic materials 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 36
- 239000011737 fluorine Substances 0.000 claims description 36
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 23
- 208000012902 Nervous system disease Diseases 0.000 claims description 22
- 208000015114 central nervous system disease Diseases 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 22
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000019901 Anxiety disease Diseases 0.000 claims description 15
- 201000004624 Dermatitis Diseases 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 15
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 230000036506 anxiety Effects 0.000 claims description 15
- 230000036528 appetite Effects 0.000 claims description 15
- 235000019789 appetite Nutrition 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 8
- 206010012335 Dependence Diseases 0.000 claims description 8
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 8
- 208000016620 Tourette disease Diseases 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 208000024963 hair loss Diseases 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 8
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 46
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 96
- 235000019000 fluorine Nutrition 0.000 description 80
- 125000001153 fluoro group Chemical group F* 0.000 description 45
- 125000000753 cycloalkyl group Chemical group 0.000 description 24
- 0 *c1c(*N(*)*)c(c(*)ccc2)c2[n]1* Chemical compound *c1c(*N(*)*)c(c(*)ccc2)c2[n]1* 0.000 description 21
- 125000002947 alkylene group Chemical group 0.000 description 18
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 11
- 239000006186 oral dosage form Substances 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2782508P | 2008-02-11 | 2008-02-11 | |
| PCT/US2009/033822 WO2009102805A1 (en) | 2008-02-11 | 2009-02-11 | Indole compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511810A JP2011511810A (ja) | 2011-04-14 |
| JP2011511810A5 true JP2011511810A5 (https=) | 2012-04-05 |
Family
ID=40445507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546107A Withdrawn JP2011511810A (ja) | 2008-02-11 | 2009-02-11 | インドール化合物およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090318527A1 (https=) |
| EP (1) | EP2254865A1 (https=) |
| JP (1) | JP2011511810A (https=) |
| AU (1) | AU2009214724A1 (https=) |
| CA (1) | CA2715282A1 (https=) |
| WO (1) | WO2009102805A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7655691B2 (en) * | 2004-09-27 | 2010-02-02 | Sard Howard P | Indole compounds useful as serotonin selective agents |
| EP2459533A4 (en) * | 2009-07-30 | 2013-01-16 | Univ Singapore | SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT |
| EP2464227A4 (en) * | 2009-08-10 | 2013-02-20 | Galenea Corp | COMPOUNDS AND METHODS OF USE |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| EP3519816A4 (en) * | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| CA3160793A1 (en) * | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20230109765A (ko) | 2020-12-09 | 2023-07-20 | 캄테크, 인크. | 다이알킬 트립타민 및 이의 치료적 용도 |
| JP2024520485A (ja) * | 2021-05-26 | 2024-05-24 | ブライト マインズ バイオサイエンスィズ インコーポレイテッド | 複素環式化合物及びその調製方法 |
| WO2023115167A1 (en) * | 2021-12-24 | 2023-06-29 | Psylo Pty Ltd | Compounds |
| WO2023173196A1 (en) | 2022-03-18 | 2023-09-21 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CA3261749A1 (en) * | 2022-07-15 | 2024-01-18 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| IL318840A (en) * | 2022-08-11 | 2025-04-01 | Gilgamesh Pharmaceuticals Inc | Tryptamines and methods of treating mood disorders |
| WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
| WO2025000051A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| WO2025000053A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Compounds |
| WO2025099725A1 (en) | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1859798T3 (en) * | 2001-03-29 | 2016-03-21 | Lilly Co Eli | N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor |
| US7655691B2 (en) * | 2004-09-27 | 2010-02-02 | Sard Howard P | Indole compounds useful as serotonin selective agents |
-
2009
- 2009-02-11 AU AU2009214724A patent/AU2009214724A1/en not_active Abandoned
- 2009-02-11 CA CA2715282A patent/CA2715282A1/en not_active Abandoned
- 2009-02-11 EP EP09710775A patent/EP2254865A1/en not_active Withdrawn
- 2009-02-11 JP JP2010546107A patent/JP2011511810A/ja not_active Withdrawn
- 2009-02-11 WO PCT/US2009/033822 patent/WO2009102805A1/en not_active Ceased
- 2009-02-11 US US12/369,659 patent/US20090318527A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511810A5 (https=) | ||
| JP2013536188A5 (https=) | ||
| JP2012526842A5 (https=) | ||
| JP2012503008A5 (https=) | ||
| JP2014515008A5 (https=) | ||
| JP2010510976A5 (https=) | ||
| JP2009537469A5 (https=) | ||
| JP2009533410A5 (https=) | ||
| JP2011519854A5 (https=) | ||
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| JP2008524328A5 (https=) | ||
| JP2013530150A5 (https=) | ||
| JP2013531008A5 (https=) | ||
| JP2014051526A5 (https=) | ||
| JP2010520341A5 (https=) | ||
| JP2006502143A5 (https=) | ||
| JP2012504608A5 (https=) | ||
| JP2009531277A5 (https=) | ||
| JP2011513410A5 (https=) | ||
| JP2012502111A5 (https=) | ||
| CA2428039A1 (en) | Serotonergic agents | |
| JP2013526610A5 (https=) | ||
| JP2008502683A5 (https=) | ||
| NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
| JP2017512211A (ja) | アミノカルボニルカルバメート化合物 |